FDA Approves Inavolisib Breast Cancer Treatment

By Rene Pretorius

October 15, 2024

The FDA’s approval of inavolisib breast cancer treatment in combination with palbociclib and fulvestrant is significant. It provides a new treatment option for a challenging patient population. This treatment is specifically for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Patients eligible for this approval have experienced recurrence after completing adjuvant endocrine therapy.

The FoundationOne Liquid CDx assay was approved as a companion diagnostic device. This device helps identify which breast cancer patients are eligible for the inavolisib treatment regimen.

Efficacy Outcomes

– The primary efficacy outcome was assessed for progression-free survival (PFS) by investigators per RECIST version 1.1.
– The median PFS was 15.0 months (95% CI: 11.3, 20.5) for the inavolisib + palbociclib + fulvestrant arm, compared to 7.3 months (95% CI: 5.6, 9.3) for the placebo + palbociclib + fulvestrant arm (Hazard ratio 0.43 [95% CI: 0.32, 0.59], p-value < 0.0001).

Overall Survival

Although the interim analysis of overall survival did not achieve statistical significance, it suggested a trend in favor of the inavolisib regimen.

Regulatory Collaboration

This approval took place under Project Orbis, which is part of the FDA Oncology Center of Excellence. It involves collaboration with various international regulatory agencies, including the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland’s Swissmedic.

Reference url

Recent Posts

DTC telehealth partnerships
Clinical guidelines and protocols Clinical Practice Evidence-based medicine Global Health Insurance and reimbursement policies Health Policy Healthcare access Innovative medicines and medical devices Innovative Tech North America Patient-centered care 

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

Staff Writer

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
Diseases Europe Innovation Innovative Tech North America Oncology and cancer research Value-based healthcare initiatives 

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

João L. Carapinha

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
Cost-effectiveness analysis Diseases Europe Health economic evaluations Healthcare decision modelling HTA HTA Agencies Innovation Innovative medicines and medical devices Innovative Tech Oncology and cancer research 

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

João L. Carapinha

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER

SERVICES

QUICK LINKS

LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.
Made with by Frogiez
schedule a meeting